CABOZANTINIB S-MALATE
| Brand name | COMETRIQ |
|---|---|
| Active ingredient | CABOZANTINIB S-MALATE |
| Strength | EQ 20MG BASE |
| Dosage form | CAPSULE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | November 2012 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9717720 | February 2032 | product |
| 12128039 | February 2032 | product |
| 11298349 | February 2032 | product |
| 8877776 | October 2030 | substance, product |
| 11091440 | January 2030 | product |
| 11091439 | January 2030 | substance |
| 11098015 | January 2030 | use U-1617 |
| 7579473 | August 2026 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.